Novel Mutations in COL6A3 That Associated With Peters’ Anomaly Caused Abnormal Intracellular Protein Retention and Decreased Cellular Resistance to Oxidative Stress

Yue Li1,2,3†, Jing Zhang1,2,3†, Yiqin Dai1,2,3, Yidan Fan1,2,3 and Jianjiang Xu1,2,3*

1 Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China, 2 NHC Key Laboratory of Myopia, Fudan University, Shanghai, China, 3 Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, China

Peters’ anomaly (PA) is a rare form of anterior segment dysgenesis characterized by central corneal opacity accompanied by iridocorneal or lenticulo-corneal adhesions. Although genetic mutations, particularly those affecting transcription factors that function in eye development, are known to cause PA, the etiology of this disease remains poorly understood. In this study, 23 patients with PA were recruited for panel sequencing. Four out of 23 patients were found to carry variants in known PA causal genes, PITX2 and PITX3. More importantly, two homozygous mutations (NM_057164: p.Val86Ala and p.Arg689Cys) in the COL6A3 gene (collagen type VI alpha-3 chain) that correlated with the phenotype of type I PA were identified, and then validated by following whole-exome sequencing. The expression profile of the COL6A3 gene in the cornea and the impact of the mutations on protein physiological processing and cellular function were further explored. It was shown that COL6A3 presented relatively high expression in the cornea. The mutant COL6A3 protein was relatively retained intracellularly, and its expression reduced cellular resistance to oxidative stress through an enhanced endoplasmic reticulum stress response. Taken together, our findings expanded the known genetic spectrum of PA, and provided evidence for the involvement of COL6A3 or collagen VI in ocular anterior segment development, thereby offering new insight for future investigations targeting PA.

Keywords: Peters’ anomaly, anterior segment dysgenesis, COL6A3, endoplasmic reticulum stress, oxidative stress, apoptosis

INTRODUCTION

The development of ocular anterior segment structures is a precisely coordinated process that is determined by both genetic and environmental factors. In humans, this process begins from week 6 of gestation, and is characterized by the formation of the lens placode from overlying surface ectoderm. The cornea is derived after lens detachment, while several waves of tissue invade the
primary mesenchyme that lies behind the surface ectoderm, ultimately giving rise to an anterior epithelium, and a posterior endothelium, with the corneal stroma laying between these layers. A number of genes that include transcription factors, nuclear proteins, structural proteins, and enzymes are known to be involved in this sophisticated process, and defects in these key genes may lead to severe congenital anterior segment dysgenesis (ASD) (Sowden, 2007; Harissi-Dagher and Colby, 2008; Ma et al., 2019).

Peters’ anomaly (PA) is a rare form of ASD characterized by central corneal opacity, abnormal stromal structures, and defects in Descemet’s membrane, accompanied by iridocorneal or lenticulo-corneal adhesions (Peters, 1906; Stone et al., 1976; Bhandari et al., 2011; Nischal, 2015), and has an incidence of approximately 1.5 per 100,000 live births (Kurilec and Zaidman, 2014). Isolated PA can be categorized as type I characterized by the iridocorneal adhesions, or type II characterized by cataracts or lenticulo-corneal adhesions. Peters’ plus syndromes accompanied with short stature, cleft lip/palate, brachydactyly and facial dysmorphism are caused by B3GLCT mutations, which is not within the scope of this study. Most isolated PA cases are sporadic, while autosomal recessive or dominant patterns of inheritance have also been reported (Summers et al., 2008; Berker et al., 2009; Iseri et al., 2009). To date, most PA-related genes are those encoding transcription factors that are expressed in the eye or other structural components, such as FOXE3, PAX6, PITX2, FOXC1, and CYP1B1 (Weisschu et al., 2008; Arikawa et al., 2010; Matafis et al., 2011; Prokudin et al., 2014; Nischal, 2015), and these genes are also predominantly involved in several other types of ASD including aniridia, congenital cataract, and infantile glaucoma (Reis and Semina, 2011; Plaisancié et al., 2018; Ma et al., 2019). With the development of next-generation sequencing (NGS), the genetic spectrum of PA has been expanded to include TFAP2A, HCCS, NDP, SLC4A11, FLNA, and COL4A1 (Deml et al., 2014; Weh et al., 2014). However, all these identified PA-causal genes can only explain a small proportion of the disease etiology, and most PA cases still lack a clear genetic diagnosis.

Structurally, the stroma makes up approximately 90% of the cornea, and is composed of collagen lamellae that are made by the epithelial cells and some stromal cells. The transparency of the cornea results from uniformity in both size and spacing of the collagen lamellae. Therefore, as an important structural component of the cornea, collagen defects have been suggested to cause several physiological abnormalities. For example, mutations in the COL4A1 and COL4A2 genes have been shown to induce PA, posterior polymorphous corneal dystrophy (PPCD), or corneal endothelial dystrophy (Biswas et al., 2001; Deml et al., 2014). It is possible that deficiencies in other collagen-encoding genes might also affect eye function, and exploring their roles in eye development might help to better elucidate the pathogenesis of PA and other types of ASD.

NGS-based panel sequencing of genomic regions of interest has been demonstrated to be a powerful approach for screening of disease-causal variants in clinical applications (Koboldt et al., 2013; Chaitankar et al., 2016; Gupta et al., 2017; Bick et al., 2019). Previously, a predesigned gene panel covering 801 candidate genes for various eye disorders was used successfully to identify the genetic spectra of corneal dystrophies in a Han Chinese population (Zhang et al., 2019c). In this study, 23 PA patients were recruited for genetic screening using the same panel, followed by whole-exome sequencing (WES) and functional investigations to confirm novel disease-causal genes. Our results expanded current knowledge of the range of genetic variants associated with PA; more importantly, we identified COL6A3 as a potential candidate gene contributing to human type I PA.

MATERIALS AND METHODS

Patients and Clinical Evaluation
This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Eye and ENT Hospital of Fudan University. We recruited 23 isolated PA patients with their unaffected parents, and 50 normal controls from the Eye and ENT Hospital, Fudan University, Shanghai, China. Written informed consent was obtained from all the participants. Diagnosis was based on specialized ophthalmologic examinations and corneal histological examination.

Next-Generation Sequencing and Variant Analysis
Genomic DNA was extracted from peripheral blood, using the QIAGEN FlexiGene DNA Kit (Qiagen, Hamburg, Germany). Targeted region sequencing on a pre-designed panel including 801 genes was performed on all the 23 PA patients as previously described (Zhang et al., 2019b,c). One of them was further subjected to whole-exome sequencing (WES). Sequencing data that passed quality control were mapped to the hg19 assembly of the human genome using the BWA package. Variants were called using the GATK2 best practices pipeline1 and then annotated using the ANNOVAR package2.

Variant analysis was performed following an in-house bioinformatics pipeline (Zhang et al., 2019b,c). Briefly, common variants with minor allele frequency (MAF) ≥ 5% in East Asians in public databases (dbSNP144, 1000 Genome Project phase 3, Esp6500, and gnomAD) were removed. The prediction of the effect of amino acid substitution on protein function was performed through SIFT and Polyphen-2. Clustal Omega was used for analysis of sequence conservation.

Animals
Balb/c mice (6–8 weeks old) were obtained from Shanghai Laboratory Animal Center, Chinese Academy of Sciences (CAS). The mice were euthanized by cervical dislocation, and the eyeballs were fixed and sectioned for further immunofluorescence staining. Total RNA was extracted from various murine tissues. All animal experimental procedures were approved by the Animal Care and Use Committee of Shanghai Medical College, Fudan University, and complied with

\(^1\)https://software.broadinstitute.org/gatk/
\(^2\)www.openbioinformatics.org/annovar/
cDNA was reverse transcribed using the FastQuant RT Kit (TIANGEN, Beijing, China). The first strand total RNA was extracted using the RNA simple Total Real-Time PCR RNA Extraction and Quantitative kit (Mu cells). The un-transfected HCECs were regarded as cDNA. Then, HCECs were transfected with the two types collecting lentiviruses carrying wide-type or mutant lentivirus packaging plasmids psPAX2 and pMD2.G for transfected with the two pHAGE-puro plasmids, and the on the C-terminus. The cDNA were separately cloned Biometrics (Hunan, China), both containing a FLAG-tag into the pHAGE-puro vector. HEK293T cells were co- on the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Immunofluorescence Staining
For tissues, murine eyeballs or human cornea were fixed in 4% paraformaldehyde (PFA), followed by dehydration in sucrose solutions. Cells were cultured on glass coverslips until 90–95% confluence, and then fixed in 4% PFA for 20 min. Next, samples were permeabilized with 0.03% Triton X-100, blocked with 3% BSA, and stained with primary antibodies (anti-COL6A3, 1:200, Sigma-Aldrich, United States; anti-FLAG, 1:2000, MBL, Japan; anti-BiP, 1:200, Abcam, United Kingdom). Lastly, the samples were stained with secondary antibody (Alexa Fluor 555-labeled donkey anti-rabbit IgG, 1:1000; and Alexa Fluor 488-labeled donkey anti-mouse IgG, 1:1000; both from Thermo Fisher Scientific, United States). The samples were examined by confocal microscopy (Leica Microsystems, Wetzlar, Germany). All the immunofluorescence image analyses were performed by ImageJ (NIH Image, United States, Version 1.52). For quantification of the BiP protein levels, we manually delineated at least ten non-overlapped areas of interest that included only FLAG-positive cells in every three immunofluorescence pictures from three independent experiments, to obtain the fluorescence intensity of FLAG and BiP, and then calculated the averaged fluorescence intensity ratio of BiP/FLAG of each picture. Then the averaged fluorescence intensity ratios of BiP/FLAG of each group were attained for comparison.

Establishment of Cells Overexpressing Wide-Type or Mutant COL6A3
Immortalized human corneal epithelial cells (HCECs) were obtained and cultured as previously described (Zhang et al., 2019a). HEK293T cells (Shanghai Cell Bank, CAS) were cultured in DMEM (Gibco, Grand Island, NY, United States) supplemented with 10% FBS and 1% penicillin/streptomycin. A full-length wild-type human COL6A3 cDNA clone (NM_057164) and a mutant COL6A3 cDNA clone (NM_057164: c.257T > C and c.2065C > T) were obtained from YouBio Biometrics (Hunan, China), both containing a FLAG-tag on the C-terminus. The cDNA were separately cloned into the pHAGE-puro vector. HEK293T cells were co-transfected with the two pHAGE-puro plasmids, and the lentivirus packaging plasmids psPAX2 and pMD2.G for collecting lentiviruses carrying wide-type or mutant COL6A3 cDNA. Then, HCECs were transfected with the two types of lentivirus respectively, followed by puromycin selection, to obtain cells stably expressing the transgenes (WT cells and Mu cells). The un-transfected HCECs were regarded as negative control (NC).

RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted using the RNA simple Total RNA Kit (TIANGEN, Beijing, China). The first strand cDNA was reverse transcribed using the FastQuant RT Kit (TIANGEN). Quantitative real-time PCR was subsequently conducted on the ABI ViiA 7 Real-Time PCR System (Thermo Lifetech, United States) using the QuantiNova SYBR Green PCR Kit (Qiagen). Primer sequences are shown in Supplementary Table 2.

Western Blotting
Cellular proteins were extracted using cold RIPA lysis buffer (Beyotime, Shanghai, China) containing a protease inhibitor cocktail. Total proteins (30–50 µg) were separated on 10 or 12% SDS-polyacrylamide gels and then transferred onto PVDF membranes. The membranes were blocked with 5% non-fat dried milk, and then incubated with primary antibodies (anti-FLAG, 1:1000, Cell Signaling Technology; anti-BiP, 1: 1000, Abcam; anti-cleaved Caspase-3, 1:1000, Cell Signaling Technology; anti-beta-Actin-Peroxidase, 1:5000, Sigma-Aldrich) overnight at 4°C, followed by incubation with HRP-conjugated goat anti-rabbit IgG secondary antibody (1:1000, Cell Signaling Technology). Chemiluminescence solution (MilliporeSigma, United States) was used to reveal the bands. Representative blots from at least three independent experiments were shown.

CCK-8 Assay
Human corneal epithelial cells were cultured in a 96-well plate (1 × 10^4 cells per well), and treated with or without 200 µM of H_2O_2 (Sangon Biotech, Shanghai, China). At the indicated time points, 10 µL of the CCK-8 solution (Dojindo Laboratories, Kumamoto, Japan) mixed with 100 µL of the culture medium was added to each well. After a 2-h incubation, the absorbance was measured at 450 nm using a microplate reader (BioTek, United States).

Analysis of Apoptosis by Flow Cytometry
Human corneal epithelial cells were seeded in 6-well plates (2 × 10^5 cells/well). After 24 h, the cells were treated with 200 µM of H_2O_2 for 6 h. The cells were then collected and double stained with Annexin V-FITC and propidium iodide (PI) for 15 min in the dark (BD Pharmingen, San Diego, CA, United States), followed by flow cytometry that was performed on a Beckman CoulterMoFlo XDP. The percentages of early or late apoptotic cells were calculated using FlowJo software version 7.6 (BD Pharmingen). Representative images from at least three independent experiments were shown.

Statistical Analysis
All quantitative data were expressed as means ± standard deviation of at least three independent experiments. Multiple group comparisons were conducted through one-way ANOVA followed by Bonferroni test with homoscedasticity, or Tamhane’s T2 test with heteroscedasticity. For two group comparisons, statistical significance was calculated by Student’s t-test. A P-value < 0.05 was considered significant. All the calculations were performed with SPSS 22.0 (IBM Corp. Armonk, NY, United States).
RESULTS

Panel Sequencing Indicated a Mutation Detection Rate of 17.4% in Isolated PA Patients

Twenty-three patients with isolated PA were recruited, as well as their unaffected parents. The clinical characteristics are depicted in Table 1. Most patients (18/23) were diagnosed with type I PA, and 16 patients were affected bilaterally. Among them, nine patients have presented with glaucoma since the diagnoses or during the follow-ups. After panel sequencing, three reported PA-causal variants (PITX2 NM_001204399: p.Pro64Arg, and PITX3 NM_005029: p.Ala214fs, p.Gly219fs) (Weisschu et al., 2006; Aldahmesh et al., 2011; Zazo et al., 2018) were found in four patients. The mutation detection rate was 17.4%, and all of them were affected bilaterally. More interestingly, we found one patient with type I PA carrying two novel homozygous mutations in the COL6A3 gene (collagen type VI alpha-3 chain, NM_057164: p.Val86Ala and p.Arg689Cys), whose role in PA etiology remains unclear (Figure 1A and Table 2).

Whole-Exome Sequencing Confirmed the Association of COL6A3 Mutations With Type I Peters’ Anomaly

The patient carrying COL6A3 mutations was a Han Chinese boy with bilateral corneal opacity (Figure 1B), born to healthy parents after an uneventful pregnancy. The ultrasound biomicroscopy examination revealed bilateral corneal degeneration, corneal thickening, and a shallow anterior chamber, accompanied with iridocorneal adhesion and almost closed anterior angles. After penetrating keratoplasty of his left eye, corneal histological examination also supported the diagnosis of type I PA (Figure 1C). During the follow-ups, the patient did not develop glaucoma. WES was performed on this patient for further validation. In accordance with previous panel sequencing results, considering parents’ genotype and gene function still prioritized that COL6A3 was likely to be associated with this PA patient (Supplementary Table 1).

The COL6A3 gene encodes the alpha-3 chain of collagen VI, which is important for organizing matrix components. These two COL6A3 mutations were both located within the von Willebrand factor type A domains that are involved in multiprotein complexes (Figure 1D). Sequence conservation analysis showed that the two residues were quite conserved among vertebrates, especially among mammals (Figure 1E). Taken together, these findings suggested that homozygous mutations in COL6A3 could be novel candidate variants associated with human PA.

COL6A3 Was Highly Expressed in the Cornea

To obtain insight into the expression features of the COL6A3 gene, we compared its expression profile in various mouse tissues using RT-qPCR, and found that it was highly expressed in the lung, cornea, and lymph nodes (Figure 2A). Immunofluorescence staining showed that the COL6A3 protein was predominantly localized to the corneal epithelium, with limited expression in the corneal stroma and endothelium. Subtle protein expression of Col6a3 was also observed in the mouse iris, ciliary body, and retina (Figures 2B,C). Immunofluorescence staining in the immortalized human corneal epithelial cells (HCECs) confirmed abundant COL6A3 expression, particularly in the cytoplasm (Figure 2D).

Next, the major COL6A3 transcript expressed in the human cornea, NM_057164 was used as a template to generate COL6A3 overexpression constructs (Supplementary Figure 1). Then HCECs were transduced with lentiviral vectors expressing either the wide-type or mutant COL6A3 cDNA. Both constructs induced the high expression of the transgenes, as determined by RT-qPCR and western blotting (WT vs un-transfected: P = 0.002; MU vs un-transfected: P = 0.004, Figure 3A; WT vs MU: P = 0.020, Figure 3B).

Mutant COL6A3 Protein Was Retained Intracellularly

As a key constitution of collagen VI, the COL6A3 protein is known to actively participate in collagen assembly, as well as collagen secretion to the extracellular matrix (ECM). Therefore, we first investigated whether the identified mutations affected the normal physiological processing of the COL6A3 protein. HCECs transfected with either wide-type (WT) or mutant (MU) cDNA were treated with cycloheximide (CHX, 5 µg/mL) to suppress protein synthesis, for comparing the intracellular elimination rates of the COL6A3 protein. The results showed a markedly slower elimination rate for mutant COL6A3 than for its wide-type form, particularly within the first hour of CHX treatment (Figure 3C). Both mutant and wide-type COL6A3 were completely eliminated after 3 h of CHX treatment.

We next examined whether these overexpressed COL6A3 proteins could be normally processed by intrinsic cellular degradation machineries, such as autophagy or the ubiquitylation pathway. In the WT group, treatment with specific inhibitors for autophagy (Pepstatin A, 10 µM; and E-64, 10 µM, both from Sigma-Aldrich) or ubiquitylation (MG132, 10 µM, Selleck, United States) efficiently restored the reduction of intracellular COL6A3 protein levels due to CHX treatment (untreated vs CHX: P = 0.004; CHX vs CHX + inhibitors: P = 0.043 and

---

**TABLE 1** Summary of clinical characteristics of recruited patients.

|                         | n = 23 |
|-------------------------|--------|
| Average age at first surgery (month) | 12.3 ± 9.6 |
| Male                    | 13 (57%) |
| Bilateral cornea affected | 16 (70%) |
| Diagnosis               |        |
| Type I Peters’ anomaly  | 18 (78%) |
| Type II Peters’ anomaly | 5 (22%)  |
| With glaucoma           | 9 (39%) |
| Discoveries in DNA sequencing |        |
| Known mutations         | PITX2 (1) / PITX3 (3) |
| Novel candidate gene    | COL6A3 (1) |
FIGURE 1 | COL6A3 was a novel candidate gene associated with type I Peters' anomaly (PA). (A) Summary of the analysis of panel sequencing data for 23 patients with PA. Three reported variants in four patients, and one novel candidate gene were identified. (B) Photographs of corneas in the patient with type I PA. OD: oculus dexter (right eye), OS: oculus sinister (left eye). (C) Hematoxylin and eosin (HE)-stained corneal tissue sections; black arrows indicate the disordered lamellar arrangement with neoangiogenesis, and white arrows indicate the adhesion between cornea and iris. (D) Validation of the two novel homozygous mutations (NM_057164: c.2065C>T, p.Arg689Cys and c.257T>C, p.Val86Ala) by Sanger sequencing. (E) Conservation analysis on the two mutant residues across species.

TABLE 2 | Summary of analysis of panel sequencing.

| Gene              | Nucleotide change | Zygosity | Protein change | Mutation type | PolyPhen2 | SIFT | 1000G | gnom AD |
|-------------------|-------------------|----------|----------------|---------------|-----------|------|-------|---------|
| With reported variants |                   |          |                |               |           |      |       |         |
| PITX2 NM_001204399 | c.191C>G          | Heterozygous | p.Pro64Arg     | Missense      | Damaging  | Damaging | 0     | 0       |
| PITX3 NM_006029   | c.640-666del      | Heterozygous | p.Ala214fs     | Frameshift    | N/A       | N/A   | 0     | 0       |
| PITX3 NM_006029   | c.656-657insGCCGC | Heterozygous | p.Gly219fs     | Frameshift    | N/A       | N/A   | 0     | 0       |

| Novel candidate gene | Nucleotide change | Zygosity | Protein change | Mutation type | PolyPhen2 | SIFT | 1000G | gnom AD |
|----------------------|-------------------|----------|----------------|---------------|-----------|------|-------|---------|
| COL6A3 NM_057164    | c.2065C>T         | Homozygous | p.Arg689Cys    | Missense      | Damaging  | Damaging | 0.004 | 0.0019  |
| COL6A3 NM_057164    | c.257T>C          | Homozygous | p.Val86Ala     | Missense      | Damaging  | Tolerant | 0.0089 | 0.0152  |

P = 0.136 respectively, Figure 3D). However, it was intriguing to find that the mutant COL6A3 protein was not sensitive to ubiquitylation- or autophagy-associated degradation. Compared with cells treated with CHX alone, the amount of intracellular COL6A3 protein in the MU group did not show a significant increase in the presence of MG132 (P = 0.649). When autophagy inhibitors were applied, the level of the mutant COL6A3 protein even slightly decreased (P = 0.379, Figure 3D). Therefore, these
results suggested that the mutant COL6A3 might be retained intracellularly, in line with its observed lower elimination rate.

**Intracellular Retention of Mutant COL6A3 Increased Endoplasmic Reticulum Stress**

Subcellular localization information obtained from the COMPARTMENTS database indicated that the intracellular COL6A3 protein was predominantly localized to the endoplasmic reticulum (ER). Given the emerging evidence of ER stress in relation with several corneal diseases (Gould et al., 2007; Chen et al., 2013; Han et al., 2016; Okumura et al., 2017; Wang et al., 2017), we next examined whether cells containing the retained mutant COL6A3 protein presented features of ER stress. When compared with the WT group, the level of BiP, an ER stress marker, in FLAG-positive cell (over-expressing COL6A3 protein), was significantly higher in the MU group ($P = 0.037$; Figures 4A,C). Moreover, the difference was even greater when the cells were exposed to 200 µM of H$_2$O$_2$ ($P = 0.000003$; Figures 4B,C). The higher BiP expression in the MU group was also supported by western blotting analysis, although the difference of the BiP/FLAG ratio did not reach statistical significance, probably due to the inclusion of FLAG-negative cells (BiP/FLAG, WT vs MU: $P = 0.0198$; BiP/Acitn, WT-H$_2$O$_2$ vs MU-H$_2$O$_2$: $P = 0.0102$; Figure 4D).

**Mutant COL6A3 Affected Cell Survival and Apoptosis**

Because intracellular retention of mutant COL6A3 triggered ER stress, next we explored whether cell survival was influenced. Under normal culture conditions, no evident difference was observed in cell morphology or growth rate either among un-transfected HCECs, or those WT or MU cells. We further
The mutant COL6A3 protein was retained intracellularly. (A) Validation of the overexpression of wide-type or mutant COL6A3 in human corneal epithelial cell lines (HCECs) after transduction with lentiviral particles by RT-qPCR (WT vs un-transfected: \( P = 0.002 \); MU vs un-transfected: \( P = 0.004 \)). The \( P \)-values were calculated by Student’s t-test for two group comparisons. (B) Validation of the overexpression of wide-type or mutant COL6A3 in human corneal epithelial cell lines (HCECs) after transduction with lentiviral particles by western blotting (WT vs MU: \( P = 0.020 \)). The COL6A3 protein level of WT or MU cells was visualized using an anti-FLAG antibody. The \( P \)-values were calculated by Student’s \( t \)-test for two group comparisons. (C) WT and MU cells were treated with 5 \( \mu \)g/mL cycloheximide (CHX) for 0.5, 1, 1.5, 2, and 3 h, respectively. Quantification of intracellular COL6A3 protein levels in WT or MU cells were determined by western blotting using an anti-FLAG antibody, and relative COL6A3 protein quantities were plotted and illustrated over time. (D) WT and MU cells were treated with 10 \( \mu \)M Pepstatin A/E-64d or 10 \( \mu \)M MG132, in the presence of 5 \( \mu \)g/mL CHX for 1 h. The intracellular COL6A3 protein levels in WT or MU cells were determined by western blotting using an anti-FLAG antibody. The graphs showed quantification of intracellular COL6A3 protein from western blotting bands; values were the average with standard deviation obtained from three independent experiments (WT group: untreated vs CHX: \( P = 0.004 \); CHX vs CHX + MG132: \( P = 0.043 \); MU group: untreated vs CHX: \( P = 0.040 \)). The \( P \)-values were calculated by one-way ANOVA test, followed by Bonferroni test. NC: the un-transfected HCECs. * \( P < 0.05 \), ** \( P < 0.01 \), *** \( P < 0.001 \).

examined cell viability in response to \( \text{H}_2\text{O}_2 \) treatment for different periods (Figure 5A). Compared with the un-transfected group, the WT cells were more viable and resistant to \( \text{H}_2\text{O}_2 \) stimulation after 6 h, or 18 h of treatment (\( P = 0.0002 \) and \( P = 0.021 \), respectively). In contrast, the overexpression of mutant COL6A3 led to a remarkable decrease in the cell survival rate earlier after 3 h (\( P = 0.025 \)), while the difference in cell viability between MU and WT groups was more evident in response to \( \text{H}_2\text{O}_2 \) exposure for 6 h and 18 h (\( P = 0.00014 \) and \( P = 0.000005 \), respectively).

Analysis of apoptosis by Annexin V/PI double staining also indicated that the overexpression of wide-type COL6A3 protected cells against \( \text{H}_2\text{O}_2 \)-induced apoptosis. Compared with the un-transfected group, the proportion of apoptotic cells in the WT group decreased by nearly 20%; the difference was more pronounced for late apoptotic cells, but did not reach significance (Figure 5B). The apoptotic rate in the MU cells was slightly higher than that of the un-transfected group, implying that mutations may neutralize the protective effect of overexpressed wide-type COL6A3.
against H₂O₂-induced apoptosis. Compared with WT cells, the percentage of total apoptosis in MU cells was significantly higher with H₂O₂ stimulation \( (P = 0.032) \). Consistently, the level of active caspase-3 was significantly lower in the WT group than in either the MU group or the un-transfected group (Active Caspase-3/FLAG: WT-H₂O₂ vs MU-H₂O₂: \( P = 0.042 \); Active Caspase-3/Actin: WT-H₂O₂ vs un-transfected-H₂O₂: \( P = 0.030 \); WT-H₂O₂ vs MU-H₂O₂: \( P = 0.026 \); Figure 5C).

Taken together, this study suggested COL6A3 as a novel candidate gene contributing to human PA. The newly identified COL6A3 mutations induced intracellular protein retention, and
Li et al.

FIGURE 5 | Cell survival was decreased and apoptosis was increased in cells overexpressing mutant COL6A3. (A) Cell viability of un-transfected, WT, and MU cells in response to H\textsubscript{2}O\textsubscript{2} stimulation (200 µM) for 3, 6, and 18 h, respectively, as determined by CCK-8 assay. For cell viability comparisons after 6 h treatment with homoscedasticity, the \( P \)-values were calculated by one-way ANOVA test, followed by Bonferroni test. For cell viability comparisons after 3 h and 18 h treatment with heteroscedasticity, the \( P \)-values were calculated through Tamhane’s T2 test. (B) Representative scattergram of apoptotic HCECs. The un-transfected, WT, and MU groups stimulated or not stimulated with H\textsubscript{2}O\textsubscript{2} for 6 h were assessed for apoptosis through flow cytometry based on Annexin V/propidium iodide (PI) double staining. The percentage of early/late apoptotic cells (%) below in each individual group was calculated from three independent experiments (WT vs MU in total apoptosis with H\textsubscript{2}O\textsubscript{2} stimulation: \( P = 0.032 \)). The \( P \)-values were calculated by one-way ANOVA test, followed by Bonferroni test. (C) Detection of apoptosis by caspase-3 activation. Cells treated with 200 µM of H\textsubscript{2}O\textsubscript{2} for 12 h were harvested and cell lysates were prepared for western blotting to detect the levels of active caspase-3. Beta-actin and FLAG was used as the loading control. The column graph showed quantification of active caspase-3 protein from western blotting bands; values were the average with standard deviation obtained from three independent experiments (Active Caspase-3/FLAG: WT-H\textsubscript{2}O\textsubscript{2} vs MU-H\textsubscript{2}O\textsubscript{2}: \( P = 0.042 \); Active Caspase-3/Actin: WT-H\textsubscript{2}O\textsubscript{2} vs un-transfected-H\textsubscript{2}O\textsubscript{2}: \( P = 0.030 \); WT-H\textsubscript{2}O\textsubscript{2} vs MU-H\textsubscript{2}O\textsubscript{2}: \( P = 0.026 \)). The \( P \)-values were calculated through Student’s t-test and Tamhane’s T2 test. NC: the un-transfected HCECs. *\( P < 0.05 \), **\( P < 0.01 \), ***\( P < 0.001 \).

enhanced the ER stress response, thereby leading to reduced cell viability under oxidative stress.

DISCUSSION

In this study, panel screening of 23 PA patients found three reported variants in established PA causal genes. The mutation detection rate was only 17.4% in isolated PA patients, which was much lower than the detection rate of other ocular diseases with strong genetic components involved (Patel et al., 2019; Zhang et al., 2019c). Our findings revealed that current knowledge on the genetic contributors associated with isolated PA was far from understood, and thereby genetic screening on PA patients might be urgent needed.

Importantly, followed by WES validation, we demonstrated COL6A3 as a novel candidate gene contribution to human type I PA. The mutant COL6A3 protein exhibited a markedly slower intracellular elimination rate than the wide-type form, and was not sensitive to the typical intracellular degradation machineries, indicating that mutations in the COL6A3 protein might lead to its abnormal intracellular retention. Subsequently, an enhanced ER stress response, followed by decreased cellular resistance to oxidative stress was observed in cells expressing the mutant form of COL6A3.

Collagen VI beaded microfibrils are found in the ECM of virtually all tissues. The domain structure of collagen VI is encoded by three genes, COL6A1, COL6A2, and COL6A3. Three additional new chains that only existed in mammals, encoded by COL6A4, COL6A5, and COL6A6, share a common evolutionary history with COL6A3 (Fitzgerald et al., 2008). Among them, the longest alpha-3 chain encoded by COL6A3 is more essential for the stability and microfibril assembly of collagen VI molecules (Lamand et al., 1998; Lamandé et al., 2006). Previously, dominant and recessive mutations in these key genes have been found in a spectrum of muscle disorders ranging from the mild Bethlem myopathy to the severe Ullrich congenital muscular dystrophy. In addition to muscle defects, affected patients or mice also present with skin and tendon features, underlining the important roles of collagen VI in the ECM of numerous other tissues (Bönnemann, 2011; Bernardi and Bonaldo, 2013; Pan et al., 2013). It is quite interesting to find that almost all
the reported mutations that associated with muscular dystrophy were located after the 10th exon in the longest transcript of COL6A3. However, the dominant transcript isoforms in the cornea do not contain these exons (shown in Supplementary Figure 1). The mutation associated with collagen VI-related myopathy usually caused the shortened alpha-3 chain, followed by the abnormal secretion, and even led to the complete absence of collagen VI. At the same time, the mutations also led to the mitochondrial dysfunction, defective autophagy, and increased apoptosis, all participating in the pathogenesis of collagen VI muscular dystrophy (Bönnemann, 2011; Bernardi and Bonaldo, 2013). Therefore, different mutations in COL6A3 may cause abnormalities in different organs/tissues, differing in the spatial expression abundance of different transcripts.

Collagen VI is shown to be abundantly expressed in the cornea (Engvall et al., 1986; Zimmermann et al., 1986; Delaigue et al., 1995) and in vitro studies have suggested that it is actively involved in corneal development. For example, Takahashi et al. (1993) showed that corneal proteoglycans, which are responsible for maintaining corneal hydration, rigidity, and transparency, are associated with collagen VI in the developing rabbit cornea. Doane et al. (1992, 1996, 1998) demonstrated that collagen VI localization not only exhibits spatial and temporal variations during corneal development, but also promotes the adhesion and localization not only exhibits spatial and temporal variations during corneal development. A recent large-scale genome-wide association study demonstrated the contribution of COL6A3 small nucleotide polymorphisms to keratoconus susceptibility, linking variation in the collagen VI encoding gene with a specific ocular disease for the first time (Khawaja et al., 2019). Here, the identification of novel COL6A3 mutations associated with human PA in this study agrees well with previous reports that have highlighted the critical role of collagen VI in corneal development.

The ER is a membranous tubular network with functions in cellular protein biosynthesis and lipid and calcium homeostasis. Genetic defects, as well as a wide range of external stimuli, can induce the accumulation of misfolded or unfolded proteins in the ER, thereby triggering the unfolded protein response and inducing apoptosis. Indeed, intracellular accumulation of mutant proteins has been observed in many corneal dystrophies (Gould et al., 2007; Jun et al., 2011; Bernardi and Bonaldo, 2013; Chen et al., 2013; Allen et al., 2016; Han et al., 2016; Okumura et al., 2017; Wang et al., 2017), highlighting that a “mutant protein accumulation-increased ER stress-reduced cell viability” pathway might be a critical contributor to disease pathogenesis. In addition, the alpha-5 and alpha-6 chains of collagen VI were shown to be retained inside the cells under a particular circumstance. The alpha-3 chain may behave like the alpha-5/6 chain, as they share much similarity in structure and function (Fitzgerald et al., 2008). In the current study, given the known subcellular localization of COL6A3 in the ER, we hypothesized that there might be an interplay between the novel PA-related COL6A3 mutations and ER function. In agreement with our assumption, we demonstrated that the mutations led to intracellular protein retention and rendered the cells more vulnerable to ER stress, thereby reducing cellular resistance to oxidative stress.

It is worth noting that if only considering variant allele frequency, it is questionable to conclude that the two COL6A3 variants are causal, since their allele frequencies in the general population were not low enough (1.5% and 0.1% MAF in East Asians), making it difficult to classify them as pathogenic causal variants for PA. However, PA is a subtype of ASD, and there are several pieces of evidence already showing that ASD phenotypes often exhibit variable expressivity and incomplete penetrance pointing to a complex etiology, implying that reduced penetrance might be a possibility. Therefore, in order to further support the contribution of the mutant protein to PA pathogenesis, we presented intensive functional data to support the variants being detrimental. Our results clearly demonstrated the variants’ pathogenic impacts on cellular function, leading to intracellular protein retention, and rendering cells more vulnerable to oxidative stress. Thus, we suggested that the observation of several carriers in the general population might be due to the decreased penetrance of this disease, which was also observed in other PA-related genes (Bejjani et al., 2000).

Our study also had several limitations. First, the data presented here can only explain the effect of mutant COL6A3 on exacerbating ER stress, and the ensuing decreased cell viability. However, the protective effect of the abundant level of wide-type COL6A3 protein shown in this study, as well as the associated underlying mechanisms, remains unclear. In fact, there were some previous studies showing the cytoprotective role of collagen VI via interacting apoptosis and oxidative damage in muscles (Irwin et al., 2003; Bönnemann, 2011; Bernardi and Bonaldo, 2013). Besides, some other studies have found that a lack of collagen VI in neural cells led to spontaneous apoptosis and defective autophagy, indicating its protective role during physiological aging or under stress (Cheng et al., 2009, 2011; Cescon et al., 2016). They are all consistent with the results in this study to some extent, and the protective effect of COL6A3 and its mechanisms need to be further investigated. Second, we only examined the influence of mutant COL6A3 within the cell, and it remains unclear whether the mutations also affect collagen secretion into the ECM. Finally, since PA is a quite rare disease, we were unable to find recurrent COL6A3 mutations in other unrelated cases at this moment. It is possible that only one variant was pathogenic, or their combined effect contributed to disease pathogenesis. Given the real mutated situation in this PA patient, and to mimic it, we investigated the two COL6A3 mutations together at this stage. Also, we cannot fully exclude the possibility that the two mutations identified here were just the tags of another real causal variant, and thereby further screening on this interested region in more PA patients is needed.

In conclusion, we obtained a mutation detection rate of 17.4% in isolated PA patients, highlighting the urgent need of expanding the genetic spectrum of PA through screening more patients. Also, we suggested COL6A3 as a novel candidate gene contributing to human PA. Mutations in the COL6A3 protein resulted in its intracellular retention, and reduced cell viability through an enhanced ER stress response, indicating that these effects might be involved in PA pathogenesis. To the best of
our knowledge, this is the first study showing the critical role of COL6A3 in ocular segment dysgenesis, i.e., PA, and our findings may aid in the future development of gene therapy for this rare disease.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study can be found in the figshare database at 10.6084/m9.figshare.1010144.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of Eye and ENT Hospital of Fudan University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. The animal study was reviewed and approved by Animal Care and Use Committee of Shanghai Medical College, Fudan University. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

JX and JZ designed the study. YL and JZ performed the experiments, analyzed the data, and drafted the manuscript. YL, YF, and YD collected the clinical data. JX, YD, and YF revised the manuscript. All authors read and approved the final manuscript.

**REFERENCES**

Aldahmesh, M. A., Khan, A. O., Mohamed, J., and Alkuraya, F. S. (2011). Novel recessive BSFP2 and PITX3 mutations: Insights into mutational mechanisms from consanguineous populations. *Genet. Med.* 13, 978–981. doi: 10.1097/GIM. 0b013e3182263d5

Allen, E. H. A., Courtney, D. G., Atkinson, S. D., Moore, J. E., Mairs, L., Poulsen, E. T., et al. (2018). Keratin 12 missense mutation induces the unfolded protein response and apoptosis in Meesmann epithelial cornal dystrophy. *Hum. Mol. Genet.* 25, 1176–1191. doi: 10.1093/hmg/ddw001

Arikawa, A., Yoshida, S., Yoshikawa, H., Ishikawa, K., Yamaji, Y., Arita, R. I., et al. (2010). Case of novel PITX2 gene mutation associated with Peters’ anomaly and persistent hyperplastic primary vitreous. *Eye* 24, 391–393. doi: 10.1038/eye. 2009.114

Bejani, B. A., Stockton, D. W., Lewis, R. A., Tomey, K. F., Dueker, D. K., Jabak, E. T., et al. (2000). Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus. *Hum. Mol. Genet.* 9, 367–374. doi: 10.1093/hmg/9.3.367

Berker, N., Alayan, Y., Elgin, U., Volkani-Salanci, B., Simsek, T., Akarsu, N., et al. (2009). A new autosomal dominant Peters’ anomaly phenotype expanding the anterior segment dysgenesis spectrum. *Acta Ophthalmol.* 87, 52–57. doi: 10.1111/j.1600-0420.2007.01082.x

Bernardi, P., and Bonaldo, P. (2013). Mitochondrial Dysfunction and Defective Autophagy in the Pathogenesis of Collagen VI Muscular Dystrophies. *Cold Spring Harb. Perspect. Biol.* 5:a011387. doi: 10.1101/cshperspect.a011387

Bhandari, R., Ferri, S., Whittaker, B., Liu, M., and Lazzaro, D. R. (2011). Peters Anomaly: Review of the Literature. *Cornea* 30, 939–944. doi: 10.1097/ICO. 0b013e31820156e9

Bick, D., Jones, M., Taylor, S. L., Taft, R. J., and Belmont, J. (2019). Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. *J. Med. Genet.* 56, 783–791. doi: 10.1136/jmedgenet-2019-106111

Biswas, S., Munier, F. L., Yardley, J., Hart-Holden, N., Perveen, R., and Cousin, P. (2001). Missense mutations in COL6A2, the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. *Hum. Mol. Genet.* 10, 2415–2423. doi: 10.1093/hmg/10.21.2415

Bönnermann, C. G. (2011). The collagen VI-related myopathies: muscle meets its stress. *Nat. Rev. Neurol.* 7, 379–390. doi: 10.1038/nrneurol.2011.81

Cescon, M., Chen, P., Castagnaro, S., Gregorio, I., and Bonaldo, P. (2016). Lack of collagen VI promotes neurodegeneration by impairing autophagy and inducing apoptosis during aging. *Aging* 8, 1083–1101. doi: 10.18632/aging.100924

Chaitanya, V., Karakulah, G., Ratnapriya, R., Giuste, F. O., Brooks, M. J., and Swaroop, A. (2016). Next generation sequencing technology and genomewide data analysis: Perspectives for retinal research. *Prog. Retin. Eye. Res.* 55, 1–31. doi: 10.1016/j.preteyeres.2016.06.001

Chen, S., Sun, M., Iozzo, R. V., Kao, W. W. Y., and Birk, D. E. (2013). Intracellularly-Retained Decorin Lacking the C-Terminal Ear Repeat Causes ER Stress. *Am. J. Pathol.* 183, 247–256. doi: 10.1016/j.ajpath.2013.04.001

Cheng, J. H., Lin, Y. C., Hwang, E., Huang, H. T., Chang, W. H., Liu, Y. L., et al. (2011). Collagen VI protects against neuronal apoptosis elicited by ultraviolet irradiation via an Akt/phosphatidylinositol 3-kinase signaling pathway. *Neuroscience* 183, 178–188. doi: 10.1016/j.neuroscience.2011. 03.057

Cheng, J. S., Dubal, D. B., Kim, D. H., Legleiter, J., Cheng, I. H., Yu, G. Q., et al. (2009). Collagen VI protects neurons against Abeta toxicity. *Nat. Neurosci.* 12, 119–121. doi: 10.1038/nn.2240

Delaille, O., Arbeille, B., Rossazza, C., Lemesle, M., and Roingeard, P. (1995). Quantitative analysis of immunogold labellings of collagen types I, III, IV

**FUNDING**

The study was sponsored by the National Natural Science Foundation of China (81700806, 81870630, and 81900817) and the Natural Science Foundation of Shanghai (17ZR1404400). The sponsor or funding organization had no role in the design or conduct of this research.

**ACKNOWLEDGMENTS**

We thank M. Zhu and R. Yao for technical assistance.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2020. 531986/full#supplementary-material

Supplementary Figure 1 | Screening of the major COL6A3 isoform that expressed in human cornea. (A) The electrophoresis results of PCR products from different COL6A3 isoforms in six independent human corneal samples. The product length of NM_004369 was 180 bp, while the one of NM_057164/NM_057165 was 197 bp. (B) Relatively higher expression of COL6A3 isoform NM_057164/NM_057165 in human cornea detected by RT-qPCR (N = 4, P = 0.017). (C) The structural difference between the two COL6A3 isoform-coding sequences, and locations of the COL6A3 mutations related with myopathy and PA in this study. The P-values were calculated by Student’s t-test. *P < 0.05.

Supplementary Table 1 | Variants identified by whole-exome sequencing.

Supplementary Table 2 | Primers used in PCR.
and VI in healthy and pathological human corneas. Graefes Arch. Clin. Exp. Ophthalmol. 233, 331–338. doi: 10.1007/bf00200481

Duml, B., Reis, L. M., Maheshwari, M., Griffiss, C., Bick, D., and Semina, E. V. (2014). Whole exome analysis identifies dominant COL4A1 mutations in patients with complex ocular phenotypes involving microphthalmia. Clin. Genet. 86, 475–481. doi: 10.1111/cge.12379

Doane, K. J., Howell, S. J., and Birk, D. E. (1998). Identification and functional characterization of two type VI collagen receptors, alpha 3 beta 1 integrin and NG2, during avian corneal stromal development. Invest. Ophthalmol. Vis. Sci. 39, 263–275.

Doane, K. J., Ting, W. H., McLaughlin, J. S., and Birk, D. E. (1996). Spatial and temporal variations in extracellular matrix of pericorneal and corneal regions during corneal stromal development. Exp. Eye. Res. 62, 271–283. doi: 10.1006/expr.1996.0033

Doane, K. J., Yang, C., and Birk, D. E. (1992). Corneal cell-matrix interactions: type VI collagen promotes adhesion and spreading of corneal fibroblasts. Exp. Cell. Res. 200, 490–499. doi: 10.1016/0014-4827(92)92020-r

Engwall, E., Hessle, H., and Klier, G. (1986). Molecular assembly, secretion, and matrix deposition of type VI collagen. J. Cell. Biol. 102, 703–710. doi: 10.1083/jcb.102.3.703

Fitzgerald, J., Rich, C., Zhou, F. H., and Hansen, U. (2008). Three Novel Collagen VI Chains, α(VI), α(VI), and α(VI). J. Biol. Chem. 283, 20170–20180. doi: 10.1074/jbc.M710192200

Gould, D. B., Marchant, J. K., Savinova, O. V., Smith, R. S., and John, S. W. M. (2003). Mitochondrial dysfunction and apoptosis in myopathic central corneal leukoma. J. Biol. Chem. 278, 20157–20164. doi: 10.1074/jbc.m302111200

Irwin, W. A., Bergamin, N., Sabattelli, P., Reggiani, C., Miegahighian, A., Merlini, L., et al. (2003). Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet. 35, 367–371. doi: 10.1038/ng1270

Jen, A. S., Meng, H., Ramanan, N., Matthaei, M., Chakravarti, S., Bonshek, R., et al. (2011). An alpha 2 collagen VIII transgenic knock-in mouse model of Fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis. Hum. Mol. Genet. 20, 33–42. doi: 10.1093/hmg/ddq024

Khalaja, A. P., Rojas Lopez, K. E., Hardcastle, A. J., Hammond, C. J., Jun, A. S., Meng, H., Ramanan, N., Matthaei, M., Chakravarti, S., Bonshek, R., et al. (2014). Anterior segment dysgenesis: Peters anomaly and sclerocornea. Int. Ophthalmol. Clin. 54, 21–30. doi: 10.1097/ioc.0000000000000552

Kurilec, J. M., and Zaidman, G. W. (2014). Incidence of Peters anomaly and sclerocornea. Int. Ophthalmol. Clin. 54, 21–30. doi: 10.1097/ioc.0000000000000552

Okumura, N., Kitahara, M., Okuda, H., Hashimoto, K., Ueda, E., Nakahara, M., et al. (2017). Sustained Activation of the Unfolded Protein Response Induces Cell Death in Fuchs’ Endothelial Corneal Dystrophy. Invest. Ophthalmol. Vis. Sci. 58, 3697–3707. doi: 10.1167/iovs.16-21023

Pan, T., Zhang, R., Markova, D., Arita, M., Zhang, Y., Bogdanovich, S., et al. (2013). COLA3 Protein Deficiency in Mice Leads to Muscle and Tendon Defects Similar to Human Collagen VI Congenital Muscular Dystrophy. J. Biol. Chem. 288, 14320–14331. doi: 10.1074/jbc.M112.433078

Peters, A. (1906). Über angeborene Defektbildung der Descemetschen Membran. Klin. Monbl. Augenheilkd. 44, 27–40.

Plaisancié, J., Ragge, N. K., Dohlus, H., Kaplan, I., Lehalle, D., Francannet, C., et al. (2018). FOXE3 mutations: genotype-phenotype correlations. Clin. Genet. 93, 837–845. doi: 10.1111/cge.13177

Prokudin, I., Simons, C., Grigg, J. R., Storen, R., Kumar, V., Phua, Z. Y., et al. (2014). Exome sequencing in developmental eye disease leads to identification of causal variants in GJA8, CRYGC, PAX6 and CYP1B1. Eur. J. Hum. Genet. 22, 907–915. doi: 10.1038/ejhg.2013.268

Reis, L. M., and Semina, E. V. (2011). Genetics of anterior segment dysgenesis disorders. Curr. Opin. Ophthalmol. 22, 314–324. doi: 10.1097/ICU.0b013e28849412b

Sowden, J. C. (2007). Molecular and developmental mechanisms of anterior segment dysgenesis. Eye 21, 1310–1318. doi: 10.1038/sj.eye.6702852

Stone, D. L., Kenyon, K. R., Green, W. R., and Ryan, S. J. (1976). Congenital central corneal leukaoma (Peters’ anomaly). Am. J. Ophthalmol. 81, 173–193. doi: 10.1016/0002-9394(76)90729-7

Summers, K. M., Withers, S. J., Gole, G. A., Piras, S., and Taylor, P. J. (2008). Anterior segment mesenchymal dysgenesis in a large Australian family is associated with the recurrent 17 bp duplication in PITX3. Mol. Vis. 14, 2010–2021.

Takahashi, T., Cho, H. I., Kublin, C. L., and Cintron, C. (1993). Keratan sulfate and dermatan sulfate proteoglycans associate with type VI collagen in fetal rabbit cornea. J. Histochem. Cytochem. 41, 1447–1457. doi: 10.1377/jhc.74E1845404

Wang, L., Tang, X., Lv, X., Sun, E., Wu, D., Wang, C., et al. (2017). CHST6 mutation screening and endolasmatic reticulum stress in macular corneal dystrophy. Oncotarget 8, 96301–96312. doi: 10.18632/oncotarget.22028

Weh, E., Reis, L. M., Happ, H. C., Levin, A. V., Wheeler, P. G., David, K. L., et al. (2014). Whole exome sequence analysis of Peters anomaly. Hum. Genet. 133, 1497–1511. doi: 10.1007/s00439-014-1481-x

Weisschuh, N., Dressler, P., Schuettauf, F., Wolf, C., Wissinger, B., and Graeme, E. (2006). Novel mutations of FOXC1 and PITX2 in patients with Axenfeld-Rieger malformations. Invest. Ophthalmol. Vis. Sci. 47, 3846–3852. doi: 10.1167/iovs.06-0343

Zazo, S. C., Plaisancie, J., Lupasco, T., Michot, C., Pechmeje, J., Delanne, J., et al. (2018). Identification of PITX3 mutations in individuals with various ocular developmental defects. OphthalmoLogic. Genet. 39, 314–320. doi: 10.1080/13816810.2018.1430243

Zhang, J., Dai, Y., Wu, D., and Xu, J. (2019a). Calcitriol, the Active Metabolite of Vitamin D3, Inhibits Dry Eye Related Corneal Inflammation In Vivo and In Vitro. Ocul. Immunol. Inflamm. 27, 257–265. doi: 10.1080/09273948.2017.1372486
Zhang, J., Li, Y., Fan, Y., Wu, D., and Xu, J. (2019b). Compound heterozygous mutations in SMO associated with anterior segment dysgenesis and morning glory syndrome. *Gene* 713:143973. doi: 10.1016/j.gene.2019.143973

Zhang, J., Wu, D., Li, Y., Fan, Y., Chen, H., Hong, J., et al. (2019c). Novel Mutations Associated With Various Types of Corneal Dystrophies in a Han Chinese Population. *Front. Genet.* 10:881. doi: 10.3389/fgene.2019.00881

Zimmermann, D. R., Trueb, B., Winterhalter, K. H., Witmer, R., and Fischer, R. W. (1986). Type VI collagen is a major component of the human cornea. *FEBS Lett.* 197, 55–58. doi: 10.1016/0014-5793(86)80297-6

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Zhang, Dai, Fan and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.